Highlights: -NICE UK concludes that EVAR is cost-effective -Endovascular aortic questions to be settled by individual patient data meta-analysis -Kabnick: Limitations of the RECOVERY trial -Pedrini: TASC II guidelines are little help -Profile: John Mannick
[pdfviewer width=”100%” height=”940px” beta=”true”]https://vascularnews.com/wp-content/uploads/sites/7/2016/02/42-Vascular-News_lowres.pdf[/pdfviewer]
